Funding
The CheckMate 9ER study was funded by Bristol Myers Squibb in collaboration with Ono Pharmaceutical and with Exelixis, Ipsen Pharma, and Takeda Pharmaceutical. The analysis reported here was funded by Exelixis, Inc. (Alameda, CA, USA).